Quarterly ResultMay 13, 2026, 04:08 PM
Spero Therapeutics Q1 Net Loss $7.2M; Tebipenem HBr FDA Decision June 18
AI Summary
Spero Therapeutics announced its first quarter 2026 financial results, reporting a net loss of $7.2 million, an improvement from $13.9 million in the prior year. Total revenue for the quarter significantly decreased to $0.3 million from $5.9 million year-over-year. The company also provided a business update, confirming the FDA's PDUFA date for the tebipenem HBr New Drug Application (NDA) is set for June 18, 2026. Spero Therapeutics reiterated its cash runway guidance, extending into 2028.
Key Highlights
- FDA PDUFA date for tebipenem HBr NDA is June 18, 2026.
- Q1 2026 net loss was $7.2 million, an improvement from $13.9 million in Q1 2025.
- Total revenue for Q1 2026 was $0.3 million, down from $5.9 million in Q1 2025.
- Research and development expenses decreased to $2.9 million from $13.6 million year-over-year.
- General and administrative expenses decreased to $4.9 million from $6.8 million year-over-year.
- Cash and cash equivalents were $56.1 million as of March 31, 2026.
- Company maintains cash runway guidance into 2028.